ChromaDex Revenue and Competitors
Estimated Revenue & Valuation
- ChromaDex's estimated annual revenue is currently $33.5M per year.
- ChromaDex received $5.0M in venture funding in October 2014.
- ChromaDex's estimated revenue per employee is $274,426
- ChromaDex's total funding is $81.7M.
Employee Data
- ChromaDex has 122 Employees.
- ChromaDex grew their employee count by 11% last year.
ChromaDex's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Head DTC | VP, Marketplaces | Reveal Email/Phone |
3 | Controller | Reveal Email/Phone |
4 | SVP Human Resources | Reveal Email/Phone |
5 | VP, Finance | Reveal Email/Phone |
6 | VP Quality | Reveal Email/Phone |
7 | SVP, Global Scientific & Regulatory Affairs | Reveal Email/Phone |
8 | General Counsel & Corporate Secretary | Reveal Email/Phone |
9 | SVP, Global Business Development & Sales | Reveal Email/Phone |
10 | VP R&D | Reveal Email/Phone |
ChromaDex Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $9.3M | 71 | -7% | N/A | N/A |
#2 | $14.6M | 94 | -10% | $71.2M | N/A |
What Is ChromaDex?
ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. For more, visit www.ChromaDex.com Like us on Facebook here: https://www.facebook.com/ChromaDex or follow us on Twitter @ChromaDex ChromaDex® is publicly-traded company (NASDAQ:CDXC).
keywords:N/A
$81.7M
Total Funding
122
Number of Employees
$33.5M
Revenue (est)
11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ChromaDex News
ChromaDex (NASDAQ:CDXC) Downgraded by Zacks Investment Research to Sell. Posted by admin on Apr 27th, 2022. Share on Twitter Share on Facebook Share on...
LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ: CDXC) today announced that it has appointed two new members to its Board of...
LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC) today celebrates over 250 material transfer agreements (MTAs) through the...
ChromaDex Corporation Reports Third Quarter 2021 Financial Results Total company net sales of $17.3 million for the three months ended September 30, 2021, with Tru Niagen® net sales of $14.8 million, up 24% from the prior year quarter and gross margin of 61.1% for the quarter. LOS ANGELES, CA ...
LOS ANGELES--(BUSINESS WIRE)--Mar 18, 2021-- ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the Zooming with LD investor conference. The ChromaDex management team is scheduled t ...
Other Companies in Irvine
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $12.2M | 122 | 13% | N/A |
#2 | $18.3M | 122 | N/A | N/A |
#3 | $17.7M | 122 | 6% | N/A |
#4 | $17.7M | 122 | -14% | N/A |
#5 | $17.7M | 122 | 16% | N/A |
ChromaDex Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2013-10-22 | $Undisclosed | Undisclosed | DSM Venturing | Article |
| 2014-10-01 | $5.0M | Undisclosed | Hercules Technology Growth Capital | Article |